Review



yeast transcription factor gal4 dna binding domain  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Addgene inc yeast transcription factor gal4 dna binding domain
    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) <t>Gal4-dependent</t> luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with <t>DNA-expression</t> plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Yeast Transcription Factor Gal4 Dna Binding Domain, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yeast+transcription+factor+gal4+dna+binding+domain/pmc08076676-45-36-21?v=Addgene+inc
    Average 92 stars, based on 7 article reviews
    yeast transcription factor gal4 dna binding domain - by Bioz Stars, 2026-08
    92/100 stars

    Images

    1) Product Images from "Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57 Kip2"

    Article Title: Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57 Kip2

    Journal: Frontiers in Cell and Developmental Biology

    doi: 10.3389/fcell.2021.664609

    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) Gal4-dependent luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with DNA-expression plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Figure Legend Snippet: p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) Gal4-dependent luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with DNA-expression plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.

    Techniques Used: Western Blot, Expressing, shRNA, Luciferase, Inhibition, Transfection, Construct, Stable Transfection, Activation Assay

    Strong activation of Gal-Jun activity is specific for p57 and requires both, the N -terminal and C -terminal domains of p57. (A) Gal4-dependent luciferase reporter gene experiments comparing the effect of the Cip/Kip-family members p57, p27, and p21 on c-Jun transactivation. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57, p27 or p21. pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. To represent minor activation, the y-axis is split into two segments (bottom: 0 to 15, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments. (B) Similar experiment to (A) comparing p57 and cyclin/CDK-binding deficient p57 mutant. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57 or the cyclin/CDK-binding deficient p57-CK- mutant (CK-) and pUbi-Rluc. A total of 30 h after transfection, cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from four independent experiments. (C) Schematic representation of p57 and its N -terminal and C -terminal domains. Key structural or functional regions of human p57 are indicated. Numbers above indicate positions of amino acid flanking distinct regions. Amino acid including the N -terminal (p57-Nt) and C -terminal (p57-Ct) domains are shown in brackets. (D) Experiment as described above (A) analyzing the contribution of p57-domains to the activation of Gal-Jun by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun and p57 or the indicated p57 domain mutants. A total of 30 hours after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 100, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments.
    Figure Legend Snippet: Strong activation of Gal-Jun activity is specific for p57 and requires both, the N -terminal and C -terminal domains of p57. (A) Gal4-dependent luciferase reporter gene experiments comparing the effect of the Cip/Kip-family members p57, p27, and p21 on c-Jun transactivation. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57, p27 or p21. pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. To represent minor activation, the y-axis is split into two segments (bottom: 0 to 15, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments. (B) Similar experiment to (A) comparing p57 and cyclin/CDK-binding deficient p57 mutant. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57 or the cyclin/CDK-binding deficient p57-CK- mutant (CK-) and pUbi-Rluc. A total of 30 h after transfection, cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from four independent experiments. (C) Schematic representation of p57 and its N -terminal and C -terminal domains. Key structural or functional regions of human p57 are indicated. Numbers above indicate positions of amino acid flanking distinct regions. Amino acid including the N -terminal (p57-Nt) and C -terminal (p57-Ct) domains are shown in brackets. (D) Experiment as described above (A) analyzing the contribution of p57-domains to the activation of Gal-Jun by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun and p57 or the indicated p57 domain mutants. A total of 30 hours after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 100, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments.

    Techniques Used: Activation Assay, Activity Assay, Luciferase, Expressing, Transfection, Binding Assay, Mutagenesis, Functional Assay

    JNK-independent activation of c-Jun by p57. (A) Schematic of human wildtype c-Jun, Gal-Jun and Gal-Jun4A mutant. Functional domains and phosphorylation sites in the transactivation domain (TAD) are indicated. A Gal4-DNA binding domain (DBD) fusion in frame to the aminoterminus of c-Jun or mutant c-Jun4A ranging from amino acids 1–223 is used in reporter gene experiments. (B) Gal4-dependent luciferase reporter gene experiments analyzing the role of the four major phosphorylation sites in the TAD of c-Jun in the activation by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun or the TAD phosphosite mutant Gal-Jun4A in absence or presence of p57 or the constitutive active upstream kinase of JNKs (ΔMEKK). pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) Gal-Jun which was set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 2.5, top: 50 to 2,000). Shown are the results from three independent experiments. (C) p57 does not induce serine 63 or serine 73 phosphorylation of c-Jun. Immunoblot-analysis investigating the effect of p57 on c-Jun TAD-phosphorylation. 293 cells were transfected with expression vectors for c-Jun and p57 (both HA-tagged) or the constitutive active kinase ΔMEKK. Extracts were prepared 40 h after transfection and subjected to immunoblot-analysis by the LiCor Odyssey system to visualize expression of HA-Jun and Ser 63 and Ser 73 phosphorylation simultaneously. Mixture of Ser 63 and Ser 73 phospho-specific rabbit polyclonal and anti HA mouse monoclonal antibodies were used as first antibodies followed by a mixture of goat derived secondary antibodies coupled with fluorochromes for 680 (anti mouse) or 780 nm (anti rabbit). Three images are shown. Upper: 700 nm channel, phospho-Ser 63/73; middle: 800 nm channel, HA; lower: merged pseudo-colors from channel 700 (red) and 800 (green). Note that molecular weight of HA-Jun is shifted in the presence of the constitutive active kinase ΔMEKK and appears yellow in the merged image.
    Figure Legend Snippet: JNK-independent activation of c-Jun by p57. (A) Schematic of human wildtype c-Jun, Gal-Jun and Gal-Jun4A mutant. Functional domains and phosphorylation sites in the transactivation domain (TAD) are indicated. A Gal4-DNA binding domain (DBD) fusion in frame to the aminoterminus of c-Jun or mutant c-Jun4A ranging from amino acids 1–223 is used in reporter gene experiments. (B) Gal4-dependent luciferase reporter gene experiments analyzing the role of the four major phosphorylation sites in the TAD of c-Jun in the activation by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun or the TAD phosphosite mutant Gal-Jun4A in absence or presence of p57 or the constitutive active upstream kinase of JNKs (ΔMEKK). pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) Gal-Jun which was set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 2.5, top: 50 to 2,000). Shown are the results from three independent experiments. (C) p57 does not induce serine 63 or serine 73 phosphorylation of c-Jun. Immunoblot-analysis investigating the effect of p57 on c-Jun TAD-phosphorylation. 293 cells were transfected with expression vectors for c-Jun and p57 (both HA-tagged) or the constitutive active kinase ΔMEKK. Extracts were prepared 40 h after transfection and subjected to immunoblot-analysis by the LiCor Odyssey system to visualize expression of HA-Jun and Ser 63 and Ser 73 phosphorylation simultaneously. Mixture of Ser 63 and Ser 73 phospho-specific rabbit polyclonal and anti HA mouse monoclonal antibodies were used as first antibodies followed by a mixture of goat derived secondary antibodies coupled with fluorochromes for 680 (anti mouse) or 780 nm (anti rabbit). Three images are shown. Upper: 700 nm channel, phospho-Ser 63/73; middle: 800 nm channel, HA; lower: merged pseudo-colors from channel 700 (red) and 800 (green). Note that molecular weight of HA-Jun is shifted in the presence of the constitutive active kinase ΔMEKK and appears yellow in the merged image.

    Techniques Used: Activation Assay, Mutagenesis, Functional Assay, Binding Assay, Luciferase, Expressing, Transfection, Western Blot, Derivative Assay, Molecular Weight

    p57 might recruit transcription repressors and activators to c-Jun. (A) Gal4-dependent luciferase reporter gene experiments analyzing the effect of p57-domain coexpression on p57-induced c-Jun-activation. Coexpression of p57-Ct may titrate out activators and coexpression of p57-Nt may titrate out repressors of c-Jun activation by p57. 293FR cells were cotransfected with expression plasmids for Gal-Jun, pUbi-Rluc, and p57 wildtype together with vectors expressing p57-Ct or p57-Nt or the related aminoterminal CDK-inhibitory domain of p27 (p27-Nt). A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from three independent experiments. (B) Mechanistic models for p57 in stimulating Gal-Jun transactivation function and a schematic of a putative transcription complex. (C) Model how p57 and FHL2 might act at endogenous promoters at AP-1 sites (TRE). Question mark in (B) and (C) indicates that there is no experimental proof for a direct interaction of p57 with the depicted proteins. For details see text.
    Figure Legend Snippet: p57 might recruit transcription repressors and activators to c-Jun. (A) Gal4-dependent luciferase reporter gene experiments analyzing the effect of p57-domain coexpression on p57-induced c-Jun-activation. Coexpression of p57-Ct may titrate out activators and coexpression of p57-Nt may titrate out repressors of c-Jun activation by p57. 293FR cells were cotransfected with expression plasmids for Gal-Jun, pUbi-Rluc, and p57 wildtype together with vectors expressing p57-Ct or p57-Nt or the related aminoterminal CDK-inhibitory domain of p27 (p27-Nt). A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from three independent experiments. (B) Mechanistic models for p57 in stimulating Gal-Jun transactivation function and a schematic of a putative transcription complex. (C) Model how p57 and FHL2 might act at endogenous promoters at AP-1 sites (TRE). Question mark in (B) and (C) indicates that there is no experimental proof for a direct interaction of p57 with the depicted proteins. For details see text.

    Techniques Used: Luciferase, Activation Assay, Expressing, Transfection



    Similar Products

    92
    Addgene inc yeast transcription factor gal4 dna binding domain
    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) <t>Gal4-dependent</t> luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with <t>DNA-expression</t> plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Yeast Transcription Factor Gal4 Dna Binding Domain, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yeast+transcription+factor+gal4+dna+binding+domain/pmc08076676-45-36-21?v=Addgene+inc
    Average 92 stars, based on 1 article reviews
    yeast transcription factor gal4 dna binding domain - by Bioz Stars, 2026-08
    92/100 stars
      Buy from Supplier

    90
    Promega dna-binding domain yeast gal4 transcription factor (gal4dbd
    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) <t>Gal4-dependent</t> luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with <t>DNA-expression</t> plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Dna Binding Domain Yeast Gal4 Transcription Factor (Gal4dbd, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yeast+transcription+factor+gal4+dna+binding+domain/pmc03840207-97-6-14?v=Promega
    Average 90 stars, based on 1 article reviews
    dna-binding domain yeast gal4 transcription factor (gal4dbd - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Promega dna-binding domain of yeast gal4 transcription factor gal4dbd
    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) <t>Gal4-dependent</t> luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with <t>DNA-expression</t> plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Dna Binding Domain Of Yeast Gal4 Transcription Factor Gal4dbd, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yeast+transcription+factor+gal4+dna+binding+domain/pm24022864-97-6-14?v=Promega
    Average 90 stars, based on 1 article reviews
    dna-binding domain of yeast gal4 transcription factor gal4dbd - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson full-length onzin fusion protein with the dna-binding domain of the yeast gal4 transcription factor
    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) <t>Gal4-dependent</t> luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with <t>DNA-expression</t> plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Full Length Onzin Fusion Protein With The Dna Binding Domain Of The Yeast Gal4 Transcription Factor, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yeast+transcription+factor+gal4+dna+binding+domain/pm16170375-201-0-12?v=Becton+Dickinson
    Average 90 stars, based on 1 article reviews
    full-length onzin fusion protein with the dna-binding domain of the yeast gal4 transcription factor - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology antibodies raised against the dna-binding domain of the yeast transcription factor gal4
    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) <t>Gal4-dependent</t> luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with <t>DNA-expression</t> plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.
    Antibodies Raised Against The Dna Binding Domain Of The Yeast Transcription Factor Gal4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/yeast+transcription+factor+gal4+dna+binding+domain/10__1042_slash_bj20040620-95-12-20?v=Santa+Cruz+Biotechnology
    Average 90 stars, based on 1 article reviews
    antibodies raised against the dna-binding domain of the yeast transcription factor gal4 - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) Gal4-dependent luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with DNA-expression plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57 Kip2

    doi: 10.3389/fcell.2021.664609

    Figure Lengend Snippet: p57 activates AP-1-dependent promoters by inducing c-Jun transactivation independent of FHL2. (A) Protein levels of FHL2 and p57 in different cell lines. 100 μg of total protein extract were analyzed by immunoblotting for FHL2 and p57 using a mouse monoclonal FHL2- and a rabbit polyclonal p57-specific antibody. CEM, human leukemic; HEL, human erythroleukemic; HL-1, mouse cardiac muscle; WM35, human melanoma; 293, human embryonic kidney; MCF-7, human breast cancer; HRT-18, human colon cancer; U2OS, human osteosarcoma; HeLa, human cervix carcinoma. The unspecific band at 70 kD ( ∗ ) after probing for p57 was used to judge equal loading. (B) Knockdown of FHL2 using four different doxycyclin-inducible shRNAs in stable pools of lentivirally transduced HRT-18 cells. Western blot analysis of extracts obtained from HRT-18 cells. The expression of shRNAs was induced by the addition of doxycycline (1 μg/mL) for 72 h. Cells expressing shRNA targeting luciferase mRNA (shLuc) served as a control. The FHL2-specific antibody revealed efficient (sh215, sh718) and less efficient (sh428, sh598) inhibition of FHL2 expression. GAPDH served as a loading control. (C) Regulation of an artificial AP-1-dependent promotor (schematic representation top panel) by p57. HRT-18.sh215 cells either untreated (– Doxy) or treated with 1 μg/mL doxycycline (+ Doxy) for 72 hours were transfected with 5xTRE-Luc reporter gene construct and 10 ng pUbi-Rluc (expressing renilla luciferase as a transfection control) together with the p57 expression vectors as indicated. A total of 48 h after transfection, cells were harvested and a Dual luciferase assays performed. Relative promoter activities were expressed as firefly luciferase activities normalized for renilla-luciferase activities. Shown are the mean values ± SD from six independent experiments. (D) Gal4-dependent luciferase reporter gene experiments comparing the effect of p57 on c-Jun and c-Fos transactivation. 293 cells with stably integrated Gal4-dependent luciferase reporter gene (293FR) were transfected with DNA-expression plasmids for Gal-DBD, Gal-Jun or Gal-Fos and p57. Schematic representation of the reporter construct is shown in the top panel. In addition, 10 ng pUbi-Rluc expressing renilla luciferase were cotransfected as control. A total of 30 h after transfection, cells were extracted and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (–) for Gal-Jun and Gal-Fos which are set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 15, top: 100 to 2,250). Shown is the mean ± SD from three independent experiments. (E) Gal4-dependent luciferase reporter gene experiments analyzing effect of p57 on c-Jun transactivation. HRT-18 cells with stably integrated Gal4-dependent luciferase reporter gene (HRT-18FR) were transfected with DNA-expression plasmids for Gal-Jun, p57 and the indicated shRNAs. pUbi-Rluc (expressing renilla luciferase) was cotranfected as a transfection control. shco was used as a control shRNA not targeting any known mRNA. 72 hours after transfection, cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (“–”/“shco”) cells which is set to 1. Shown is the mean ± SD from three independent experiments. Level of significance is indicated. ** = Highly significant, n.s. = not significant.

    Article Snippet: See for sequence information and cloning procedure. pcDNA3-FLAG-Fos WT was a gift from John Blenis (Addgene plasmid # 8966; http://n2t.net/addgene:8966 ; Addgene_8966 ) and is described elsewhere ( ). pSG424-Gal-c-fos expresses a fusion protein of the yeast transcription factor GAL4 DNA binding domain (aa 1–147) fused to rat c-Fos (aa 213–380) where DNA-binding and dimerization domains are absent and cloned by PCR-amplification of the corresponding codon using pcDNA3-FLAG-Fos WT as a template (oligonucleotide sequences, see ). pFC-MEKK (Agilent) expresses constitutive active MEKK (aa 380–672) which activates JNK.

    Techniques: Western Blot, Expressing, shRNA, Luciferase, Inhibition, Transfection, Construct, Stable Transfection, Activation Assay

    Strong activation of Gal-Jun activity is specific for p57 and requires both, the N -terminal and C -terminal domains of p57. (A) Gal4-dependent luciferase reporter gene experiments comparing the effect of the Cip/Kip-family members p57, p27, and p21 on c-Jun transactivation. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57, p27 or p21. pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. To represent minor activation, the y-axis is split into two segments (bottom: 0 to 15, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments. (B) Similar experiment to (A) comparing p57 and cyclin/CDK-binding deficient p57 mutant. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57 or the cyclin/CDK-binding deficient p57-CK- mutant (CK-) and pUbi-Rluc. A total of 30 h after transfection, cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from four independent experiments. (C) Schematic representation of p57 and its N -terminal and C -terminal domains. Key structural or functional regions of human p57 are indicated. Numbers above indicate positions of amino acid flanking distinct regions. Amino acid including the N -terminal (p57-Nt) and C -terminal (p57-Ct) domains are shown in brackets. (D) Experiment as described above (A) analyzing the contribution of p57-domains to the activation of Gal-Jun by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun and p57 or the indicated p57 domain mutants. A total of 30 hours after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 100, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57 Kip2

    doi: 10.3389/fcell.2021.664609

    Figure Lengend Snippet: Strong activation of Gal-Jun activity is specific for p57 and requires both, the N -terminal and C -terminal domains of p57. (A) Gal4-dependent luciferase reporter gene experiments comparing the effect of the Cip/Kip-family members p57, p27, and p21 on c-Jun transactivation. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57, p27 or p21. pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. To represent minor activation, the y-axis is split into two segments (bottom: 0 to 15, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments. (B) Similar experiment to (A) comparing p57 and cyclin/CDK-binding deficient p57 mutant. 293FR cells were cotransfected with DNA-expression plasmids for Gal-DBD, Gal-Jun and p57 or the cyclin/CDK-binding deficient p57-CK- mutant (CK-) and pUbi-Rluc. A total of 30 h after transfection, cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from four independent experiments. (C) Schematic representation of p57 and its N -terminal and C -terminal domains. Key structural or functional regions of human p57 are indicated. Numbers above indicate positions of amino acid flanking distinct regions. Amino acid including the N -terminal (p57-Nt) and C -terminal (p57-Ct) domains are shown in brackets. (D) Experiment as described above (A) analyzing the contribution of p57-domains to the activation of Gal-Jun by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun and p57 or the indicated p57 domain mutants. A total of 30 hours after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 100, top: 100 to 1,500). Shown is the mean ± SD from three independent experiments.

    Article Snippet: See for sequence information and cloning procedure. pcDNA3-FLAG-Fos WT was a gift from John Blenis (Addgene plasmid # 8966; http://n2t.net/addgene:8966 ; Addgene_8966 ) and is described elsewhere ( ). pSG424-Gal-c-fos expresses a fusion protein of the yeast transcription factor GAL4 DNA binding domain (aa 1–147) fused to rat c-Fos (aa 213–380) where DNA-binding and dimerization domains are absent and cloned by PCR-amplification of the corresponding codon using pcDNA3-FLAG-Fos WT as a template (oligonucleotide sequences, see ). pFC-MEKK (Agilent) expresses constitutive active MEKK (aa 380–672) which activates JNK.

    Techniques: Activation Assay, Activity Assay, Luciferase, Expressing, Transfection, Binding Assay, Mutagenesis, Functional Assay

    JNK-independent activation of c-Jun by p57. (A) Schematic of human wildtype c-Jun, Gal-Jun and Gal-Jun4A mutant. Functional domains and phosphorylation sites in the transactivation domain (TAD) are indicated. A Gal4-DNA binding domain (DBD) fusion in frame to the aminoterminus of c-Jun or mutant c-Jun4A ranging from amino acids 1–223 is used in reporter gene experiments. (B) Gal4-dependent luciferase reporter gene experiments analyzing the role of the four major phosphorylation sites in the TAD of c-Jun in the activation by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun or the TAD phosphosite mutant Gal-Jun4A in absence or presence of p57 or the constitutive active upstream kinase of JNKs (ΔMEKK). pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) Gal-Jun which was set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 2.5, top: 50 to 2,000). Shown are the results from three independent experiments. (C) p57 does not induce serine 63 or serine 73 phosphorylation of c-Jun. Immunoblot-analysis investigating the effect of p57 on c-Jun TAD-phosphorylation. 293 cells were transfected with expression vectors for c-Jun and p57 (both HA-tagged) or the constitutive active kinase ΔMEKK. Extracts were prepared 40 h after transfection and subjected to immunoblot-analysis by the LiCor Odyssey system to visualize expression of HA-Jun and Ser 63 and Ser 73 phosphorylation simultaneously. Mixture of Ser 63 and Ser 73 phospho-specific rabbit polyclonal and anti HA mouse monoclonal antibodies were used as first antibodies followed by a mixture of goat derived secondary antibodies coupled with fluorochromes for 680 (anti mouse) or 780 nm (anti rabbit). Three images are shown. Upper: 700 nm channel, phospho-Ser 63/73; middle: 800 nm channel, HA; lower: merged pseudo-colors from channel 700 (red) and 800 (green). Note that molecular weight of HA-Jun is shifted in the presence of the constitutive active kinase ΔMEKK and appears yellow in the merged image.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57 Kip2

    doi: 10.3389/fcell.2021.664609

    Figure Lengend Snippet: JNK-independent activation of c-Jun by p57. (A) Schematic of human wildtype c-Jun, Gal-Jun and Gal-Jun4A mutant. Functional domains and phosphorylation sites in the transactivation domain (TAD) are indicated. A Gal4-DNA binding domain (DBD) fusion in frame to the aminoterminus of c-Jun or mutant c-Jun4A ranging from amino acids 1–223 is used in reporter gene experiments. (B) Gal4-dependent luciferase reporter gene experiments analyzing the role of the four major phosphorylation sites in the TAD of c-Jun in the activation by p57. 293FR cells were cotransfected with DNA-expression plasmids for Gal-Jun or the TAD phosphosite mutant Gal-Jun4A in absence or presence of p57 or the constitutive active upstream kinase of JNKs (ΔMEKK). pUbi-Rluc (expressing renilla luciferase) served as a transfection control. A total of 30 h after transfection cells were harvested and subjected to dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) Gal-Jun which was set to 1. For showing lower fold activations, y-axis is split into two segments (bottom: 0 to 2.5, top: 50 to 2,000). Shown are the results from three independent experiments. (C) p57 does not induce serine 63 or serine 73 phosphorylation of c-Jun. Immunoblot-analysis investigating the effect of p57 on c-Jun TAD-phosphorylation. 293 cells were transfected with expression vectors for c-Jun and p57 (both HA-tagged) or the constitutive active kinase ΔMEKK. Extracts were prepared 40 h after transfection and subjected to immunoblot-analysis by the LiCor Odyssey system to visualize expression of HA-Jun and Ser 63 and Ser 73 phosphorylation simultaneously. Mixture of Ser 63 and Ser 73 phospho-specific rabbit polyclonal and anti HA mouse monoclonal antibodies were used as first antibodies followed by a mixture of goat derived secondary antibodies coupled with fluorochromes for 680 (anti mouse) or 780 nm (anti rabbit). Three images are shown. Upper: 700 nm channel, phospho-Ser 63/73; middle: 800 nm channel, HA; lower: merged pseudo-colors from channel 700 (red) and 800 (green). Note that molecular weight of HA-Jun is shifted in the presence of the constitutive active kinase ΔMEKK and appears yellow in the merged image.

    Article Snippet: See for sequence information and cloning procedure. pcDNA3-FLAG-Fos WT was a gift from John Blenis (Addgene plasmid # 8966; http://n2t.net/addgene:8966 ; Addgene_8966 ) and is described elsewhere ( ). pSG424-Gal-c-fos expresses a fusion protein of the yeast transcription factor GAL4 DNA binding domain (aa 1–147) fused to rat c-Fos (aa 213–380) where DNA-binding and dimerization domains are absent and cloned by PCR-amplification of the corresponding codon using pcDNA3-FLAG-Fos WT as a template (oligonucleotide sequences, see ). pFC-MEKK (Agilent) expresses constitutive active MEKK (aa 380–672) which activates JNK.

    Techniques: Activation Assay, Mutagenesis, Functional Assay, Binding Assay, Luciferase, Expressing, Transfection, Western Blot, Derivative Assay, Molecular Weight

    p57 might recruit transcription repressors and activators to c-Jun. (A) Gal4-dependent luciferase reporter gene experiments analyzing the effect of p57-domain coexpression on p57-induced c-Jun-activation. Coexpression of p57-Ct may titrate out activators and coexpression of p57-Nt may titrate out repressors of c-Jun activation by p57. 293FR cells were cotransfected with expression plasmids for Gal-Jun, pUbi-Rluc, and p57 wildtype together with vectors expressing p57-Ct or p57-Nt or the related aminoterminal CDK-inhibitory domain of p27 (p27-Nt). A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from three independent experiments. (B) Mechanistic models for p57 in stimulating Gal-Jun transactivation function and a schematic of a putative transcription complex. (C) Model how p57 and FHL2 might act at endogenous promoters at AP-1 sites (TRE). Question mark in (B) and (C) indicates that there is no experimental proof for a direct interaction of p57 with the depicted proteins. For details see text.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57 Kip2

    doi: 10.3389/fcell.2021.664609

    Figure Lengend Snippet: p57 might recruit transcription repressors and activators to c-Jun. (A) Gal4-dependent luciferase reporter gene experiments analyzing the effect of p57-domain coexpression on p57-induced c-Jun-activation. Coexpression of p57-Ct may titrate out activators and coexpression of p57-Nt may titrate out repressors of c-Jun activation by p57. 293FR cells were cotransfected with expression plasmids for Gal-Jun, pUbi-Rluc, and p57 wildtype together with vectors expressing p57-Ct or p57-Nt or the related aminoterminal CDK-inhibitory domain of p27 (p27-Nt). A total of 30 h after transfection cells were harvested and subjected to Dual luciferase assays. Renilla-normalized values are expressed as fold activation relative to control transfected (Co.) which is set to 1. Shown is the mean ± SD from three independent experiments. (B) Mechanistic models for p57 in stimulating Gal-Jun transactivation function and a schematic of a putative transcription complex. (C) Model how p57 and FHL2 might act at endogenous promoters at AP-1 sites (TRE). Question mark in (B) and (C) indicates that there is no experimental proof for a direct interaction of p57 with the depicted proteins. For details see text.

    Article Snippet: See for sequence information and cloning procedure. pcDNA3-FLAG-Fos WT was a gift from John Blenis (Addgene plasmid # 8966; http://n2t.net/addgene:8966 ; Addgene_8966 ) and is described elsewhere ( ). pSG424-Gal-c-fos expresses a fusion protein of the yeast transcription factor GAL4 DNA binding domain (aa 1–147) fused to rat c-Fos (aa 213–380) where DNA-binding and dimerization domains are absent and cloned by PCR-amplification of the corresponding codon using pcDNA3-FLAG-Fos WT as a template (oligonucleotide sequences, see ). pFC-MEKK (Agilent) expresses constitutive active MEKK (aa 380–672) which activates JNK.

    Techniques: Luciferase, Activation Assay, Expressing, Transfection